Comparable stake leader
Seah H. Lim
SEC ownership of Emmaus Life Sciences, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000822370.
Disclosed value leader
Seah H. Lim
Comparable rows
1/9
Latest evidence
16 Sep 2024
- Public ticker
- EMMA on OTC
- Parsed ownership sources
- 3/4/5 and 13D/G
- Largest SEC-reported holder
- Seah H. Lim
- Latest 13D/G holder
- Seah H. Lim
- Latest parsed ownership date
- 16 Sep 2024
- Issuer CIK
- 0000822370
- Issuer location
- Torrance, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Emmaus Life Sciences, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Seah H. Lim
Disclosed value leader
Seah H. Lim
Comparable rows
1/9
Latest evidence
16 Sep 2024
3/4/5
13D/G
Lead comparable stake: 6.5%
8 rows are not safely comparable across share classes.
13D/G row: Seah H. Lim
Showing 1-8 of 9 holder rows.
Quick read
Seah H. Lim leads the comparable SEC ownership view at 6.5%.
1 of 9 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Seah H. Lim's linked filing trail.
Comparable ownership
Top 1
Seah H. Lim
6.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 9 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Seah H. Lim |
3/4/5
13D/G
Director · Seah H. Lim, M.D., Ph.D.
|
6.5%
from 13D/G
|
$613,861
4,706,626 shares
mixed-class rows
|
— | 16 Sep 2024 |
| Wei Peu Zen |
3/4/5
Director
|
—
mixed-class rows
|
$316,952
6,139,031 shares
mixed-class rows
|
— | 01 Feb 2024 |
| Willis C. Lee |
3/4/5
Co-President & COO, Director
|
—
mixed-class rows
|
$133,443
995,718 shares
mixed-class rows
|
— | 26 Feb 2024 |
| Charles W. Stark |
3/4/5
CSO & EVP Clinical Development
|
—
class O/S missing
|
$30,000
200,000 shares
|
— | 01 Feb 2024 |
| George Sekulich |
3/4/5
Co-President & CCO, Director
|
—
class O/S missing
|
$30,000
200,000 shares
|
— | 01 Feb 2024 |
| Yasushi Nagasaki |
3/4/5
CFO
|
—
class O/S missing
|
$30,000
200,000 shares
|
— | 01 Feb 2024 |
| Ian Harvey Zwicker |
3/4/5
Director
|
—
class O/S missing
|
$15,000
100,000 shares
|
— | 01 Feb 2024 |
| Lui Alfred Fu Kong |
3/4/5
Director
|
—
class O/S missing
|
$2,118
42,358 shares
|
— | 03 Jan 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 06 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to Emmaus Life Sciences, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Seah H. Lim
Net 12M change
$0
Latest report
16 Apr 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Seah H. Lim | Director | $613,861 | Mixed | 16 Sep 2024 | ||
| Wei Peu Zen | Director | $316,952 | Mixed | 01 Feb 2024 | ||
| Willis C. Lee | Co-President & COO, Director | $133,443 | Mixed | 26 Feb 2024 | ||
| Charles W. Stark | CSO & EVP Clinical Development | $30,000 | Mixed | 01 Feb 2024 | ||
| George Sekulich | Co-President & CCO, Director | $30,000 | Mixed | 01 Feb 2024 | ||
| Yasushi Nagasaki | Cfo | $30,000 | Mixed | 01 Feb 2024 | ||
| Ian Harvey Zwicker | Director | $15,000 | Mixed | 01 Feb 2024 | ||
| Lui Alfred Fu Kong | Director | $2,118 | Mixed | 03 Jan 2022 | ||
| Lori Teranishi | Director | $908 | Mixed | 06 Jan 2022 | ||
| Yutaka Niihara | Chairman and CEO, Director, 10%+ Owner | Mixed | 12 Jan 2023 | |||
| Jon Kuwahara | Director | Mixed | 01 Oct 2024 | |||
| Huy du Henry | Director | Mixed | 16 Apr 2026 |
Recent insider transactions for Emmaus Life Sciences, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.